Nabota, a purified botulinum toxin type A, is approved for both medical and cosmetic use in numerous countries across the globe, though it has not yet received approval from the U.S. Food and Drug Administration (FDA). Its primary approvals are concentrated in Asia, Latin America, and the Middle East, with a significant presence established over the past decade. The product is developed by South Korea’s Daewoong Pharmaceutical and has gained recognition as a key player in the global neurotoxin market, often positioned as a competitor to well-established brands like Botox.
The journey of Nabota’s approvals is a testament to its manufacturer’s global strategy. It first gained traction in its home market, South Korea, where it received approval from the Ministry of Food and Drug Safety (MFDS). This domestic success provided a strong foundation for international expansion. The company then strategically targeted markets with streamlined regulatory pathways or where there was a demand for high-quality, cost-effective alternatives to existing products. A pivotal moment in its global acceptance was its approval in 2019 by the European Medicines Agency (EMA) under the brand name Letybo for the treatment of glabellar lines (frown lines between the eyebrows). While the EMA approval is for the European Economic Area, it serves as a significant endorsement of the product’s safety and efficacy profile, influencing regulatory decisions in other regions.
To understand the geographic spread of Nabota’s approvals, the following table provides a detailed, non-exhaustive overview of key countries and their specific approved indications.
| Region | Country/Area | Approved Indications (Cosmetic) | Approved Indications (Medical) | Regulatory Body / Year of Notable Approval |
|---|---|---|---|---|
| Asia | South Korea | Improvement of glabellar lines | Blepharospasm, Cervical dystonia, Strabismus | MFDS (Original Approval) |
| Thailand | Glabellar lines | Blepharospasm | Thai FDA | |
| Philippines | Moderate to severe glabellar lines | Not widely approved for medical use | FDA Philippines | |
| Latin America | Mexico | Facial wrinkles | Blepharospasm, Hemifacial spasm | COFEPRIS |
| Middle East | United Arab Emirates | Glabellar lines | Various movement disorders | Ministry of Health & Prevention |
| Saudi Arabia | Moderate to severe glabellar lines | Not widely approved for medical use | SFDA | |
| Europe | European Economic Area | Temporary improvement of glabellar lines (as Letybo) | Under review/approved for certain therapeutic uses in some member states | EMA (2019) |
The distinction between cosmetic and medical approvals is crucial. Cosmetic use typically refers to the temporary improvement in the appearance of moderate to severe frown lines. Medical use, however, encompasses a range of conditions driven by muscle overactivity. These include chronic conditions like cervical dystonia (a painful condition where neck muscles contract involuntarily), blepharospasm (uncontrolled blinking or eye closure), spasticity in adults following a stroke, and even severe primary axillary hyperhidrosis (excessive underarm sweating). The fact that Nabota has secured approvals for these therapeutic areas in multiple countries underscores its clinical versatility beyond aesthetics. The clinical data supporting these approvals often involves large-scale Phase III trials demonstrating non-inferiority to onabotulinumtoxinA (Botox) in terms of both efficacy and safety.
From a regulatory science perspective, each country’s health authority evaluates a product like Nabota based on a comprehensive dossier containing data on its manufacturing process, purity, potency, and results from pre-clinical and clinical studies. The core of Nabota’s technology, as promoted by Daewoong, is its unique purification process using a patented technology called DFP (Daewoong Finest Pure). The company claims this process yields a highly pure 900kDa botulinum toxin type A complex with low levels of foreign proteins, which is theorized to potentially reduce the risk of developing neutralizing antibodies. The development of neutralizing antibodies is a known, though rare, phenomenon where the body’s immune system recognizes the therapeutic protein as foreign and renders subsequent treatments less effective. This claimed high purity is a central part of the product’s value proposition when seeking approvals globally.
The global botulinum toxin market is intensely competitive, and regulatory approvals are directly tied to market share. Nabota’s approval in a particular country is not just a regulatory milestone but a commercial one. It allows Daewoong and its distribution partners to compete directly with Allergan’s Botox, Ipsen’s Dysport, and other toxins in that territory. For instance, its approval in Europe opened up a market of over 30 countries. In Latin America, approvals in major markets like Mexico position it as an accessible option for a large population. The commercial strategy often involves highlighting key differentiators such as cost-effectiveness and its high purity profile to both clinicians and patients.
It is impossible to discuss Nabota’s approval status without addressing the elephant in the room: the United States. Daewoong Pharmaceutical, in partnership with Evolus, has been pursuing FDA approval for years under the proposed brand name Jeuveau. This process has been complex and fraught with challenges, including a protracted intellectual property dispute with Allergan and Medytox. After a rigorous review, the FDA approved Jeuveau (prabotulinumtoxinA-xvfs) for the temporary improvement of moderate to severe glabellar lines in adults in 2019. This approval was a landmark event, effectively granting Nabota (marketed as Jeuveau) access to the world’s largest aesthetic market. The FDA’s approval was based on the pivotal Phase III clinical program, which enrolled over 2,100 patients and demonstrated safety and efficacy.
Looking at the landscape from a patient and practitioner perspective, the geographic patchwork of approvals means that the availability of Nabota is highly location-dependent. A dermatologist in Seoul has the option to use it for both cosmetic frown lines and medical conditions like blepharospasm, backed by years of local clinical experience and post-market surveillance data. A clinician in Riyadh may primarily use it for cosmetic indications, while a neurologist in Mexico City might prescribe it for movement disorders. This variability influences clinical practice, treatment options, and cost structures for patients around the world. The ongoing collection of real-world evidence in these diverse markets continues to build the long-term safety profile of the product.
The future trajectory of Nabota’s global approvals will likely focus on expanding its medical indications in existing markets and entering new, emerging markets in Southeast Asia and Africa. Furthermore, as the patent exclusivity of first-generation toxins like Botox expires in various regions, the door opens for biosimilar and bio-better competitors like Nabota to gain further ground. Each new approval adds another piece to the complex puzzle of Nabota’s standing as a globally recognized neurotoxin, solidifying its role as a significant alternative for healthcare providers and patients seeking effective treatments for both aesthetic concerns and debilitating medical conditions.